267 related articles for article (PubMed ID: 38089455)
1. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer.
; ;
Cancer Innov; 2022 Jun; 1(1):25-54. PubMed ID: 38089455
[TBL] [Abstract][Full Text] [Related]
2. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
3. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
Brufsky AM
Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
[TBL] [Abstract][Full Text] [Related]
4. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
5. PI3K/Akt/mTOR inhibitors in breast cancer.
Lee JJ; Loh K; Yap YS
Cancer Biol Med; 2015 Dec; 12(4):342-54. PubMed ID: 26779371
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer.
du Rusquec P; Blonz C; Frenel JS; Campone M
Ther Adv Med Oncol; 2020; 12():1758835920940939. PubMed ID: 32782489
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer.
Browne IM; Okines AFC
Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927964
[TBL] [Abstract][Full Text] [Related]
8. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.
Chia S; Gandhi S; Joy AA; Edwards S; Gorr M; Hopkins S; Kondejewski J; Ayoub JP; Califaretti N; Rayson D; Dent SF
Curr Oncol; 2015 Feb; 22(1):33-48. PubMed ID: 25684987
[TBL] [Abstract][Full Text] [Related]
9. Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Chang DY; Ma WL; Lu YS
Ther Clin Risk Manag; 2021; 17():193-207. PubMed ID: 33707948
[TBL] [Abstract][Full Text] [Related]
10. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.
Zhang X; Li XR; Zhang J
Curr Cancer Drug Targets; 2013 Feb; 13(2):175-87. PubMed ID: 23215724
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
Zhu K; Wu Y; He P; Fan Y; Zhong X; Zheng H; Luo T
Cells; 2022 Aug; 11(16):. PubMed ID: 36010585
[TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
15. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.
Alves CL; Ditzel HJ
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901954
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.
Arena F
Cancer Manag Res; 2014; 6():389-95. PubMed ID: 25336989
[TBL] [Abstract][Full Text] [Related]
18. Recent clinical advances in PI3K inhibitors on colorectal cancer.
Zhu M; Jin Q; Xin Y
Pharmazie; 2021 Dec; 76(12):568-573. PubMed ID: 34986950
[TBL] [Abstract][Full Text] [Related]
19. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Kaklamani VG; Richardson AL; Arteaga CL
Oncologist; 2019 Mar; 24(3):305-312. PubMed ID: 30651399
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
